Acronym:
CA224-047
ACTRN/NCT /ethics:
Scientific title:
Summary of trial and patient characteristics
| Cancer Type | Melanoma & other skin | ||
|---|---|---|---|
| Trial Type | Treatment | ||
| Phase | Phase II, Phase III | Tumour Stream | Melanoma |
| Age Range | 18 years and older | Cancer Stage | Metastatic or Widespread |
| Sex | Both | Anticipated Start Date | |
| Molecular Target | Anticipated End Date | ||
| Cancer Type | Melanoma & other skin |
|---|---|
| Trial Type | Treatment |
| Phase | Phase II, Phase III |
| Age Range | 18 years and older |
| Sex | Both |
| Molecular Target | |
| Tumour Stream | Melanoma |
| Cancer Stage | Metastatic or Widespread |
| Anticipated Start Date | |
| Anticipated End Date |
Trial Summary
A randomized, double-blind phase 2/3 study of Relatlimab combined with Nivolumab versus Nivolumab in participants with previously untreated metastatic or unresectable melanoma.
Lay Summary
Sponsor / Cooperative group
Participating Hospitals
| Hospital | Clinical Trial Coordinator | Phone | Principal Investigator | Recruitment Status | |
|---|---|---|---|---|---|
| Flinders Medical Centre | Alex Scott-Hoy | alex.scott-hoy@sa.gov.au | 08 8204 4830 | Amitesh Roy | Completed |